OTC Markets OTCPK - Delayed Quote USD

Camurus AB (publ) (CAMRF)

50.97

0.00

(0.00%)

At close: January 29 at 3:00:00 PM EST

Camurus AB (CAMRF) Q3 2024 Earnings Call Highlights: Record Profit and Revenue Growth Amid ...

Camurus AB (CAMRF) reports a robust quarter with significant revenue and profit growth, while navigating regulatory hurdles and market dynamics.

GuruFocus.com 2 months ago

CAMX.ST
Camurus reports positive results from Phase III trial of acromegaly treatment

The trial's primary focus was on safety over a year of treatment, with CAM2029 demonstrating a favourable profile.

Clinical Trials Arena 6 months ago

CAMX.ST
Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

Camurus (NASDAQ: CAMX) (STO: CAMX) today announced positive, final, topline results from the 52-week Phase 3 open-label ACROINNOVA 2 (NCT04125836) study, which evaluated safety and efficacy of the company's once-monthly octreotide subcutaneous (SC) depot (CAM2029). The study included a total of 135 patients with acromegaly who were biochemically controlled (IGF-1≤1xULN) or uncontrolled on stable doses of standard-of-care (SoC) with first generation somatostatin ligands (SRL) at screening; of the

PR Newswire 6 months ago

CAMRF
0.00%
New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl

Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3 study1 comparing weekly and monthly subcutaneous (SC) buprenorphine injections (Buvidal®/Brixadi®) to daily sublingual buprenorphine/naloxone (SL-BPN/NX). The data presented suggests the effectiveness in individuals with opioid dependence who use fentanyl, consistent with the results from the Phase 3 study.

PR Newswire 7 months ago

CAMRF
0.00%

Performance Overview

Return	CAMRF	OMX Stockholm 30 Index
YTD	0.00%	+7.55%
1-Year	+133.68%	+12.76%
3-Year	+295.08%	+17.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Camurus AB (publ) (CAMRF)

Camurus AB (CAMRF) Q3 2024 Earnings Call Highlights: Record Profit and Revenue Growth Amid ...

Camurus reports positive results from Phase III trial of acromegaly treatment

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl

Performance Overview